Proteomics‐Empowered Microfluidic‐SERS Immunoassay for Identifying and Detecting Biomarkers of Micropapillary Lung Adenocarcinoma
Advanced Science · 2025-07 · 12 (25)
DOI: 10.1002/advs.202501336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 03.05.2025. Verfasst von Dechun Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Optoelectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technolo…. Hauptthemen laut MEDLINE: Lung Neoplasms, Proteomics, Biomarkers, Tumor, Spectrum Analysis, Raman. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science Fund Program for Excellent Young Scientists of Fujian, Joint Funds for the Innovation of Science and Technology, Fujian Province.
Abstract (Originalsprache)
The presence of a micropapillary (MPP) component is a crucial determinant of surgical strategies for lung adenocarcinoma (LUAD), yet reliable blood biomarkers for predicting MPP⁺ LUAD remain elusive. Here, we integrate 4D label‐free quantitative proteomics, a nanomixing‐enhanced microfluidic surface‐enhanced Raman spectroscopy (SERS) platform, and machine learning to sensitively identify and validate blood protein biomarkers associated with MPP⁺ LUAD. Comparative proteomics reveal 44 differentially expressed proteins (DEPs) between MPP⁺ and MPP⁻ LUADs, with bioinformatics uncovering their roles in MPP⁺ LUAD formation. To enable sensitive, multiplex detection of 4 upregulated DEPs, the nanomixing effect is leveraged to enhance target protein‐SERS barcode interactions while minimizing nonspecific binding to antibody‐functionalized gold electrodes. The SERS barcode cocktail allows simultaneous detection of the 4 selected DEPs. Machine learning models based on SERS detection effectively distinguish MPP⁺ from MPP⁻ LUAD patients, as well as LUAD patients from healthy donors. This approach demonstrates strong diagnostic potential for early, non‐invasive MPP detection in LUAD, advancing nanotechnology‐driven disease diagnosis and monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Optoelectronic Science and Technology for Medicine of Ministry of Education, Fujian Provincial Key Laboratory of Photonics Technology, Fujian Normal University, Fuzhou, Fujian, 350117, China.
- Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, 350001, China.
- Department of Pathology, Clinical Oncology School of Fujian Medical University and Fujian Cancer Hospital, Fuzhou, Fujian, 350014, China.
ORCID-Profile: Jing Wang
Förderung
- National Natural Science Foundation of China
- Science Fund Program for Excellent Young Scientists of Fujian
- Joint Funds for the Innovation of Science and Technology, Fujian Province
- Guiding Projects of Fujian Province
Zitieren
APA
Zhang, D., Peng, K., Xu, H., Chen, Y., & Wang, J. (2025). Proteomics‐Empowered Microfluidic‐SERS Immunoassay for Identifying and Detecting Biomarkers of Micropapillary Lung Adenocarcinoma. Advanced Science, 12(25). https://doi.org/10.1002/advs.202501336
Vancouver
Zhang D, Peng K, Xu H, Chen Y, Wang J. Proteomics‐Empowered Microfluidic‐SERS Immunoassay for Identifying and Detecting Biomarkers of Micropapillary Lung Adenocarcinoma. Advanced Science. 2025;12(25). doi:10.1002/advs.202501336
BibTeX
@article{Zhang2025,
author = {Zhang, Dechun and Peng, Kaiming and Xu, Hui and Chen, Yanping and Wang, Jing},
title = {Proteomics‐Empowered Microfluidic‐SERS Immunoassay for Identifying and Detecting Biomarkers of Micropapillary Lung Adenocarcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {25},
doi = {10.1002/advs.202501336}
}
EUVIMED